title: Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder.
abstract: OBJECTIVE
  To determine if response to immunosuppressive treatment in motor neuron syndromes could be predicted on the basis of clinical features, anti-GM1 antibodies, or conduction block.
  
  
  METHODS
  Prospective, uncontrolled, treatment trial using prednisone for 4 months followed by intravenous cyclophosphamide (3 g/m2) continued orally for 6 months.
  
  
  METHODS
  All patients were referred to university hospital medical centers.
  
  
  METHODS
  Sixty-five patients with motor neuron syndromes were treated with prednisone; 11 patients had elevated GM1 antibody titers, and 11 patients had conduction block. Forty-five patients received cyclophosphamide, eight of whom had elevated GM1 antibodies and 10 had conduction block.
  
  
  RESULTS
  One patient responded to prednisone, and five patients responded to cyclophosphamide treatment. Only patients with a lower motor neuron syndrome and conduction block improved with either treatment. Response to treatment did not correlate with GM1 antibodies.
  
  
  CONCLUSIONS
  GM1 antibodies did not serve as a marker for improvement in patients with motor neuron syndrome treated with immunosuppressive drugs. Patients with amyotrophic lateral sclerosis failed to improve irrespective of laboratory findings.
authors.affiliation: Department of Neurology, Ohio State University, Columbus.
authors.forename: E
authors.initials: E
authors.lastname: Tan
authors.forename: D J
authors.initials: DJ
authors.lastname: Lynn
authors.forename: A A
authors.initials: AA
authors.lastname: Amato
authors.forename: J T
authors.initials: JT
authors.lastname: Kissel
authors.forename: K W
authors.initials: KW
authors.lastname: Rammohan
authors.forename: Z
authors.initials: Z
authors.lastname: Sahenk
authors.forename: J R
authors.initials: JR
authors.lastname: Warmolts
authors.forename: C E
authors.initials: CE
authors.lastname: Jackson
authors.forename: R J
authors.initials: RJ
authors.lastname: Barohn
authors.forename: J R
authors.initials: JR
authors.lastname: Mendell
mesh_terms: D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005677:G(M1) Ganglioside / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009431:Neural Conduction; D011241:Prednisone / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D007166:Immunosuppressive Agents; D005677:G(M1) Ganglioside; D003520:Cyclophosphamide; D011241:Prednisone